林可霉素联合利巴韦林治疗小儿肺炎的临床疗效及安全性研究

Study on the Clinical Efficacy and Safety of Lincomycin Combined with Ribavirin in the Treatment of Pediatric Pneumonia

目的探讨林可霉素联合利巴韦林治疗小儿肺炎的临床疗效及安全性。方法选取某院2016年7月～2018月7月的106例小儿肺炎进行研究,根据患儿病情的情况分为联合治疗组和单纯治疗组各53例,单纯治疗组采用利巴韦林治疗,联合治疗组在单纯治疗组的基础上进行林可霉素治疗,治疗1周时间,观察两组患儿的临床疗效、肺功能(FEV1/FVC、PEF和MBC)、炎性指标(IL-2、IL-6)及不良反应。结果联合治疗组的总有效率(96.4%)明显高于单纯治疗组(78.6%),有统计学意义(P<0.05);联合治疗组的FEV1/FVC、PEF和MBC水平比单纯治疗组明显增高(P<0.05);联合治疗组的IL-2、IL-6水平比单纯治疗组明显降低(P<0.05);两组患儿均无恶心、头疼、口干、嗜睡等药物不良反应。结论林可霉素联合利巴韦林治疗小儿肺炎可以有效改善患儿的肺功能,消除炎性反应,可以用于小儿肺炎的治疗。

OBJECTIVE To study the clinical efficacy and safety of lincomycin combined with ribavirin in the treatment of pediatric pneumonia. METHODS From July 2016 to July 2018,106 cases of pediatric pneumonia,depending on the condition of the child were divided into two groups,combined treatment group and simple treatment group( n = 53). The simple treatment group was treated with ribavirin.The combined treatment group was treated with lincomycin on the basis of the simple treatment group.Treatment for one week,the clinical efficacy,pulmonary function( FEV1/FVC,PEF,MBC),inflammatory index( IL-2,IL-6) and adverse reactions were observed in the two groups. RESULTS The total effective rate of the combined treatment group( 96. 4%) was significantly higher than that of the simple treatment group( 78. 6%). The FEV1/FVC,PEF and MBC of the combined treatment group were significantly higher than that of the simple treatment group( P < 0. 05),and the IL-2,IL-6 level of the combined treatment group was significantly lower than that of the simple treatment group. There were no adverse drug reactions such as nausea,headache,dry mouth,drowsiness and so on in both groups. CONCLUSION Lincomycin combined with ribavirin can effectively improve pulmonary function and eliminate inflammatory reaction in children with pneumonia.